276 results about "Antitumor therapy" patented technology

The invention discloses an anti-tumor treatment adverse reaction risk early warning method and system, and relates to the technical field of medical information processing, and the method comprises the steps: obtaining the physiological index data of a patient, and obtaining a short-term risk prediction result based on the time sequence change characteristics of the physiological index data of a deep neural network; obtaining clinical feature data of the patient, constructing a susceptibility assessment model, and analyzing correlation features of the clinical feature data through the susceptibility assessment model to obtain a baseline risk assessment result; and according to the short-term risk prediction result and the baseline risk assessment result, calculating a comprehensive risk score, and when the comprehensive risk score exceeds an early warning threshold of the corresponding adverse reaction type, triggering an early warning signal. According to the method, a double-layer risk assessment system is constructed by combining instant physiological index changes and clinical features of patients, the technical problems that an existing early warning method is insufficient in consideration of individual differences of the patients and poor in early warning timeliness are solved, and the accuracy and timeliness of early warning of adverse reactions of anti-tumor treatment are improved.

The invention discloses a preparation method and application of a zinc-manganese bimetal organic framework derived composite nano-enzyme, and belongs to the technical field of nano-materials. Zinc-manganese bimetal organic framework nanoparticles prepared by reacting ZIF-8 with manganese (III) acetylacetonate are used as a template, and are calcined at different temperatures in a tubular furnace to obtain zinc-manganese bimetal organic framework derivative composite nano-enzymes with different morphologies. The nano enzyme has peroxidase-like activity, glutathione peroxidase-like activity and catalase-like activity, and has a wide application prospect in anti-tumor treatment.

The invention provides a preparation method and application of a high-efficiency encapsulated pH-responsive drug-loaded liposome. According to the method, two-phase fluid of a medicine aqueous solution and a lipid component organic solution in a micro-channel is accurately controlled, and the efficiently encapsulated liposome is prepared from bottom to top by utilizing a micro-mixing technology. Compared with a conventional passive drug loading method which is relatively low in encapsulation efficiency in preparation of hydrophilic drug nano-liposomes, the method provided by the invention can improve the encapsulation efficiency to be close to 95% under optimized prescription and process conditions. According to the invention, by adjusting the proportion of each component in the prescription and the preparation process, the release behavior of liposome drugs such as adriamycin and the like can be adjusted, and the drug release shows pH responsiveness. Through efficient encapsulation of adriamycin and the like and pH-responsive release of the liposome dosage form, the effects of efficacy enhancement and toxicity reduction are achieved in the anti-tumor treatment aspect.

The invention discloses an MOF-CQD enzyme-sensitive FRET hydrogel diagnosis and treatment probe as well as a preparation method and application thereof, and belongs to the technical field of biomedical detection and treatment. The probe takes a carboxyl carbon quantum dot (CQD) as a donor and a metal organic framework (MOF) as an acceptor, and the donor and the acceptor are connected through a replaceable enzyme response polypeptide bridge; when the fluorescence is complete, FRET is generated to quench the CQD fluorescence, the FRET is interrupted after the target enzyme cuts off the peptide bridge, and the blue / red fluorescence ratio is changed to realize nanomole-level quantitative detection and has self-correction capability. The probe is packaged in a four-arm PEG transparent hydrogel which does not need a photoinitiator and can be quickly self-crosslinked, and can be prepared into a film, a tooth socket and the like for POCT (point-of-care testing) of parts such as an oral cavity / skin and the like. After detection, the MOF is activated by illumination of 630-660 nm to generate active singlet oxygen, so that local antibacterial or anti-tumor treatment is realized, and a diagnosis and treatment integrated scheme is constructed.

The invention provides a whole-process targeting polypeptide, a drug compound thereof, a drug delivery system and application of the whole-process targeting polypeptide. The whole-process targeting polypeptide comprises pHA and VAP which are covalently connected through a bridging structure; the VAP is LVAP, a reverse sequence polypeptide of the LVAP, DVAP or SVAP; wherein the amino acid sequence of the LVAP is as shown in SEQ ID NO: 1; the SVAP is a D-configuration polypeptide of the LVAP; the DVAP is a D-configuration polypeptide of the LVAP inverted sequence polypeptide; the bridging structure is amino-monoethylene glycol-carboxylic acid or a derivative thereof. The whole-process targeting polypeptide not only can cross a blood-brain barrier, target tumor neovascularization, cross a blood-tumor barrier, target tumor mimicry vessels, tumor cells and stem cells thereof, but also has better tumor cell affinity, anti-tumor treatment and in-vivo safety effects. Meanwhile, the drug compound or the drug delivery system has a synergistic effect after being combined with a chemotherapeutic drug, and the anti-tumor drug effect can be remarkably improved.

A photosensitizer chimera targeting PD-L1 protein, and a preparation method therefor and a use thereof. The photosensitizer chimera is of an X-R-G structure, wherein X is a photosensitizer unit, R is a linker, G is a polypeptide unit targeting PD-L1 protein, the photosensitizer is a porphyrin photosensitizer, and the excitation light wavelength of the photosensitizer is longer than 550 nm; the molar absorption coefficient at the maximum absorption wavelength longer than the wavelength of 550 nm is greater than 1000 M -1cm-1; the quantum yield of a triplet state exceeds 0.01; the linker is selected from the following structural formulas, wherein the amino side of the linker is connected to the photosensitizer unit, the carboxyl side of the linker is connected to the polypeptide unit, and n is an integer of 0-50; the binding constant of the polypeptide and h-PD-L1 is less than 20 µm. Combination therapy of immune checkpoint blockade and cytotoxicity induced by the photosensitive chimera based on photodegradation of PD-L1 protein in PD-1 / PD-L1 can cause stronger immune response than monotherapy, and thus the photosensitive chimera has great potential in enhancing antitumor therapy.

The embodiment of the invention provides breast cancer targeting nanoparticles as well as a preparation method and application thereof. According to the embodiment of the invention, the breast cancer targeting nanoparticles are synthesized by preparing the pH sensitive polymer, carrying out co-coupling modification on the pH response polymer and the folic acid albumin nano-carrier and utilizing a controlled desolvation method; the breast cancer targeting nanoparticle is combined with a nano preparation passive targeting strategy, a tumor microenvironment stimulation response strategy and a folic acid active targeting strategy, the effects of an EPR effect, PEG shedding, charge overturning, folic acid ligand-receptor combination and the like are utilized, precise targeting and specific response of tumors are achieved, and targeted accumulation of drugs in a tumor microenvironment is comprehensively improved. Therefore, the breast cancer targeting nanoparticles prepared by the embodiment have the advantages of high targeting property, drug controlled release, improvement of solubility and absorptivity of indissolvable drugs and the like, so that the curative effect of the drugs can be enhanced, the toxic and side effects can be reduced, and the breast cancer targeting nanoparticles have wide application prospects in the field of anti-tumor treatment.

The invention relates to the technical field of biological medicine, in particular to immunogen cell death enhanced nano-vesicle hydrogel and application thereof. The invention provides a 3D-printable multifunctional synergistic immunogen cell death enhanced nano-vesicle hydrogel, which is characterized in that SerMA hydrogel is used as a matrix, cell membrane nano-vesicles (N (at) ILO) loaded with a photothermal agent IR1061, a chemotherapeutic drug OXA and a tumor acidic microenvironment regulator Lon are encapsulated, initial tumor immunogen cell death is triggered through a photothermal effect, and the tumor immunogen cell death enhanced nano-vesicle hydrogel can be used for 3D printing. OXA further enhances the ICD effect, Lon regulates the acidic tumor microenvironment to improve the T cell activity, and postoperative multi-mode synergistic anti-tumor treatment is achieved; meanwhile, the hydrogel also has excellent photocuring 3D printing capability, can be used for individually constructing a filling structure matched with a postoperative defect area, has a wide application prospect, and provides a new strategy and theoretical basis for postoperative comprehensive treatment of choroidal melanoma.

The invention belongs to the technical field of microorganisms, and particularly relates to application of parabacteroides dielsii SYSU-210 and metabolites thereof in cancer treatment. The parabacteroides dieldrii is a parabacteroides dieldrii SYSU-210 strain, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.32494, and the preservation date is November 04, 2024. According to the application disclosed by the invention, by carrying out anti-tumor treatment on tumor-bearing mice with colon cancer and breast cancer by using the single parabacteroides dieldrii SYSU-210 and a metabolite thereof, the screened SYSU-210 has a good treatment effect on both the colon cancer and the breast cancer, and effector T cell infiltration in tumors of the mice in a treatment group is remarkably increased; and when the compound is combined with an immunotherapy alpha PD-1 inhibitor or a chemotherapeutic drug oxaliplatin for use, the effect of synergistically enhancing the curative effect is shown.

The present invention belongs to the technical field of cancer immunotherapy, and particularly relates to a cholesterol-modified cationic liposome tumor vaccine, a preparation method therefor, and use thereof. In order to solve the problems of poor targeting and strong side effects of TLR agonists in anti-tumor treatment, the present invention provides a cationic liposome prepared from a cholesterol-modified 1V209 molecule, a cationic lipid component, cholesterol, and DSPE-PEG2000, and then the cationic liposome and ovalbumin 5 form the tumor vaccine by electrostatic adsorption. Animal experiments show that the vaccine can induce antigen-specific CD8+ T cells, activate lymphocytes, and generate stronger antigen cross-presentation, more memory T cells, antibodies, and cytokines. Prophylactic inoculation with the vaccine can significantly delay the progression of mouse melanoma and lymphoma and prolong the survival of mice. The combination use of the vaccine and a PD-1 checkpoint inhibitor can further enhance the anti-tumor effect. Therefore, the vaccine is a promising cancer vaccine.

The invention discloses Man-PFH-ICG (at) PLGA nanoparticles as well as a preparation method and application thereof, and belongs to the technical field of composite material preparation. According to the invention, PLGA is used as a carrier, the surface of the PLGA is marked with mannose by using polylactic acid-glycolic acid (PLGA) nanoparticles (NPs), and ICG and oxygen-carrying PFH are embedded in the PLGA nanoparticles, so that the obtained Man-PFH-ICG-PLGA nanoparticles have an excellent targeting effect on a mannose receptor overexpressed on the surface of a tumor cell, and obviously promote effective endocytosis of the cell and tumor enrichment in vivo in vitro; the hypoxic environment of tumors is directly relieved; in addition, oxygen can be supplemented endogenously, ROS generated by cells is used for activating TRPA1 channels over-expressed on the surfaces of tumor cells, and therefore cell respiration is inhibited, oxygen consumption is reduced, the tumor hypoxia environment is indirectly relieved, tumor cell growth is effectively inhibited, and a new thought is added for clinical exploration of anti-tumor treatment.

The invention discloses a preparation method of an RNA targeted photosensitizer and an application of the RNA targeted photosensitizer in anti-tumor treatment, and belongs to the technical field of fine chemical engineering. The photosensitizer is modified on the basis of a fluorescent molecule parent, and the RNA targeted photosensitizer is constructed. The photosensitizer disclosed by the invention can be self-assembled into nanoparticles in an aqueous solution, shows good RNA targeting, effectively generates reactive oxygen species through I-type and II-type mechanisms, and shows excellent performance in the aspects of long-term fluorescence imaging in tumor cells and anti-tumor treatment in normal-oxygen and hypoxic environments; the fluorescence of the photosensitizer Se-cy is enhanced by about 230 times after RNA is added, and the fluorescence duration can be kept as long as 40 hours in in-vitro cells; and the fluorescent label can be kept for 4 days in vivo, shows excellent fluorescent durability, and has a remarkable anti-tumor effect on tumor-bearing mice.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a dammarane sapogenin-isatin derivative and application thereof in anti-tumor treatment. The dammarane sapogenin-isatin conjugate is constructed by taking dammarane sapogenin as a mother nucleus, deriving the dammarane sapogenin and chloroacetic acid and then introducing an indolone structural unit, and R1, R2 and R3 are as described in the claims and the specification. According to the invention, isatin fragments and ginsenoside are coupled for the first time, the anti-tumor activity of the compounds is systematically evaluated, and the action mechanism research of the compounds in colorectal cancer and other tumors is further developed. Results show that the obtained compound has relatively good anti-tumor efficacy, tumor cell selectivity, relatively low toxicity and relatively high bioavailability, and shows good patent medicine potential and wide market prospects.

The invention relates to the technical field of organoid culture, and relates to a culture system and a culture method for gastrointestinal tumor organoids for the first time, the culture system is formed by adding antioxidant active traditional Chinese medicine extracts such as naringin or polydatin on the basis of an existing culture system, when the culture system is used for culturing the gastrointestinal tumor organoid, the primary survival rate of the gastrointestinal tumor organoid and the proliferation rate after passage can be improved. Besides, the invention further provides application of the culture system of the gastrointestinal tumor organoid, the culture system and the cultured gastrointestinal tumor organoid are used for screening small-molecule targeted anti-tumor drugs, and a better in-vitro research model is provided for subsequent anti-tumor treatment.

The invention relates to the technical field of traditional Chinese medicine processing, and discloses traditional Chinese medicine processing equipment for traditional Chinese medicine anti-tumor treatment, which comprises a crushing box, the front surface of the crushing box is fixedly connected with a first motor, the output end of the first motor is provided with crushing rollers through a coupler, and the two crushing rollers are meshed with each other through a gear set; a screen is arranged in the smashing box, a suction opening of the smashing box synchronously moves along with the carding component through a suction fan and a conveying pipe, large particles which cannot pass through the screen on the screen face can be accurately and efficiently sucked up in time, and the large particles are conveyed to the top of the smashing box again through the conveying pipe and fall into the position between the two smashing rollers to be smashed again forcibly. The trouble that traditional equipment needs to be shut down to manually return materials is avoided, the materials are smashed multiple times in the single machining process, the smashing efficiency is remarkably improved, the carding plate horizontally reciprocates above the screen, large-particle materials are continuously carded, cut and smashed, and screen holes are effectively prevented from being blocked.

The invention belongs to the technical field of biomedical materials, and discloses pH-responsive injectable hydrogel as well as a preparation method and application thereof. Comprising the following steps: (1) dissolving sodium alginate in water to form a uniform solution; (2) adding a fat-soluble small molecule drug and Fe3O4 nanoparticles into the solution, carrying out high-speed shearing dispersion under an ice-water bath condition to form a drug / nano composite system, and standing; and (3) sequentially adding a calcium carbonate suspension and glucolactone into the drug / nano composite system, uniformly stirring, and incubating until the mixture is completely cured to obtain the pH-responsive injectable hydrogel. The hydrogel obtained by the invention not only has excellent injectability and pH response release performance, but also can remarkably improve the loading efficiency of fat-soluble drugs, and provides a new technical approach for realizing local anti-tumor treatment.

The invention discloses a fluorescent / photoacoustic dual-mode diagnosis and treatment probe for detection and photodynamic removal of senescent cells, a preparation method and application, the probe takes a sulfur-substituted hemicyanine dye as a parent structure, a novel bromo-glycoside ligand is covalently coupled, and a blue-green solid is obtained after gradient purification. The probe system shows a remarkable optical response characteristic on beta-galactosidase (beta-Gal) and ideal singlet oxygen (1O2) generation efficiency; an optical signal and a photodynamic therapy effect of the probe can be specifically activated by beta-galactosidase (beta-Gal) overexpressed in cancerous cells and senescent cells under a light excitation condition; the result is successfully verified in a palbociclib-induced senescence melanoma model. According to the probe disclosed by the invention, collaborative regulation and control of dual-mode visual monitoring and precise photodynamic therapy of beta-Gal enzyme activity are realized for the first time, a novel tool is provided for researching a molecular mechanism of cell aging and developing a diagnosis and treatment strategy of aging-related diseases, and the probe has a remarkable application value in the fields of anti-tumor treatment and degenerative diseases.

The invention belongs to the technical field of photosensitizer preparation and biological medicine, and particularly relates to a photosensitizer and a preparation method and application thereof. The I-type photosensitizer Nile violet NV is designed and synthesized on the basis of fluorescent dye Nile red through monatomic substitution and structural modification, and the structural formula of the I-type photosensitizer Nile violet NV is shown in the formula I. The photosensitizer based on Nile red can generate O2 <.-> after illumination, and has I-type photodynamic therapy potential; the nanomaterial has a good active oxygen generation capability in tumor cells, and is beneficial to the application of tumor photodynamic therapy. The invention proves that the compound shows an excellent anti-tumor effect in mouse solid tumors and can be widely applied to the field of anti-tumor treatment; meanwhile, the I-type photosensitizer is simple in synthesis method, good in biological safety and remarkable in tumor photodynamic therapy effect, so that the I-type photosensitizer has good practical application value.

The invention belongs to the technical field of nano materials and anti-tumor treatment medicines, and discloses cordyceps sinensis mycelium polysaccharide-copper selenide with dual effects of inducing tumor cell apoptosis and copper death as well as a preparation method and application thereof. The preparation method of the cordyceps sinensis mycelium polysaccharide-copper selenide comprises the following steps: taking cordyceps sinensis mycelium polysaccharide as a template, adopting a soft template method, reducing Na2SeO3 through Vc, and adding CuSO4 to prepare the cordyceps sinensis mycelium polysaccharide-copper selenide. The cordyceps sinensis mycelium polysaccharide-copper selenide can selectively kill tumor cells and induce apoptosis and copper death of the tumor cells at the same time, and has huge application potential in the aspect of tumor prevention and treatment.

The invention provides a method for inducing DC precursor cells in PBMC (peripheral blood mononuclear cells) to differentiate into pDC cells in vitro, which comprises the following steps: the PBMC is placed in a culture medium for culture, and the culture medium comprises the following components: GM-CSF (granulocyte-macrophage colony-stimulating factor), Poly (I: C), Flt3l, TNF-alpha, ODN2006, Compound 4, autologous plasma and an AIM-V basal culture medium; replacing or supplementing the culture medium based on the culture progress until the preset culture time is reached; and collecting the cultured cells. According to the method, the PBMC serves as a culture object, the DC precursor cells in the PBMC are finally differentiated into the pDC cells through culture, the culture method is simple, a large number of pDC cells can be conveniently and efficiently obtained in vitro, and guarantee is provided for basic research and clinical application of the pDC cells. Meanwhile, the pDC cells obtained after the culture medium is used for culturing for 7 days can secrete IFN-alpha with a relatively high level under the condition of no target cell stimulation, so that the application of the culture medium in antiviral and anti-tumor treatment is facilitated.

This application discloses a purino[1,2-a]carbazolin derivative, its preparation method, and its application. Specifically, it discloses a compound having the structure shown in Formula I, or its stereoisomers, solvates, metabolites, pharmaceutically acceptable salts, cocrystals, or prodrugs: ; wherein R1 and R2 are each independently selected from hydrogen, hydroxyl, carboxyl, substituted or unsubstituted C1-C6 alkyl, -CONH-R3, and -COO-R4; wherein R3 is a substituted or unsubstituted C1-C5 alkyl, and the substituent can be any of cyano, halogen, alkylC1-C5 alkoxy, C1-C5 alkylsulfonyl, di(C1-C5 alkyl)amino, nitrogen-containing heterocyclic, aryl, and C1-C5 heteroaryl; R4 is selected from any of substituted or unsubstituted aryl C1-C5 alkyl and nitrogen-containing saturated heterocyclic C1-C5 alkyl. This compound can be used as a TDP1 inhibitor for antitumor therapy.

The invention relates to a PD-L1 protein targeted photosensitizer chimera as well as a preparation method and application thereof. The photosensitizer chimera is of an X-R-G structure, X is a photosensitizer unit, R is a connecting arm, G is a polypeptide unit targeting PD-L1 protein, a photosensitizer is a porphyrin photosensitizer, and the excitation light wavelength of the photosensitizer is gt; the wavelength is 550nm; the molar absorption coefficient gt at the maximum absorption wavelength after the wavelength of 550 nm; 1000 M <-1 > cm <-1 >; the quantum yield of the triplet state is gt; 0.01, 0.01; the connecting arm is selected from the following structural formula: # imgabs0 #, the amino side of the connecting arm is connected with the photosensitizer unit, the carboxyl side of the connecting arm is connected with the polypeptide unit, and n is an integer of 0-50; the binding constant of the polypeptide and h-PD-L1 is lt; and 20 [mu] M. According to the photosensitive chimera disclosed by the invention, combined treatment based on immune checkpoint blocking and cytotoxic effects induced by photodegradation of PD-L1 protein in PD-1 / PD-L1 can generate immune response stronger than single treatment, and the photosensitive chimera has great potential in the aspect of enhancing anti-tumor treatment.

The present invention provides a long-acting dual-target chimeric antigen receptor, nucleic acid molecule, recombinant vector, cell, and application thereof. The dual-target chimeric antigen receptor comprises two independent transmembrane protein chains, wherein the first CAR chain targets a scFv of the first target, and the intracellular signal comprises a second signal and an intracellular transduction signal or only an intracellular transduction signal; the second CAR chain targets a scFv of the second target, and the intracellular signal comprises a costimulatory signal and a JAK enzyme activation transduction domain. The CAR-T cells prepared by the present invention have a strong and persistent killing effect on tumor cells that simultaneously express the first and second targets, and can be used for the anti-tumor treatment of solid tumors.

This invention belongs to the pharmaceutical field, specifically relating to an anti-tumor angiogenesis drug potentiator, an anti-tumor drug composition, and its application. Firstly, this invention discovers that SHCBP1 inhibitors can enhance the therapeutic effect of anti-tumor angiogenesis drugs and can be used as potentiators for anti-tumor angiogenesis drugs. Secondly, when SHCBP1 inhibitors are used in combination with anti-tumor angiogenesis drugs, or in combination with anti-tumor angiogenesis drugs and PD-1 inhibitors, tumor angiogenesis can be normalized and its window period prolonged, significantly improving the efficacy of immunotherapy, anti-angiogenesis, and anti-tumor therapy, showing broad application prospects.

The application discloses a kind of Man-PFH-ICG@PLGA nanoparticles and preparation method and application thereof, belong to composite material preparation technical field.The application uses PLGA as carrier, using polylactic acid-glycolic acid (PLGA) nanoparticles (NPs) to mark the surface of it with mannose, and ICG and oxygen-carrying PFH are embedded therein, the obtained Man-PFH-ICG@PLGA nanoparticles have excellent targeting effect on the overexpression of mannose receptor on the surface of tumor cells, significantly promote the effective endocytosis of cells in vitro and tumor enrichment in vivo, directly relieve the hypoxic environment of tumor;It can also supplement oxygen by endogenous, to activate the TRPA1 channel overexpressed on the surface of tumor cells by ROS generated by cells, so as to inhibit cell respiration, reduce oxygen consumption, indirectly relieve the hypoxic environment of tumor, effectively inhibit the growth of tumor cells, and provide a new idea for clinical exploration of antitumor therapy.

Provided are a polypeptide-conjugated drug, a method for preparing same, and use thereof. Specifically, the present invention relates to a polypeptide-conjugated drug as represented by general formula (I) and use thereof, wherein P comprises a polypeptide of formula (II), L is selected from a non-cleavable linker or a cleavable linker, and Drug is an antitumor agent. The polypeptide-conjugated drug can specifically bind to GRPr with high affinity and thereby efficiently kill tumor cells, thus providing a targeted antitumor therapy for the field of tumor treatment. P-L-Drug (I) Ser-Tyr-Gln-X1-Ala-X2-βAla-X3-X4-Nle (II)

This invention provides a chlorambucil NO donor prodrug having the structure shown in Formula (I) or a pharmaceutically acceptable salt thereof: Formula (I). It involves reacting chlorambucil with a dihaloalkane to obtain a halochlorambucil intermediate; reacting the halochlorambucil intermediate with silver nitrate to obtain the chlorambucil NO donor prodrug. This invention applies the chlorambucil NO donor prodrug to the preparation of drugs for treating tumors, such as melanoma, lymphoma, leukemia, or breast cancer. This nanosystem exhibits good NO release levels under light irradiation. Cellular experiments have demonstrated its good antitumor effect, providing a new strategy for multimodal combined antitumor therapy.

The invention discloses a core-crosslinked nano-drug based on a dual enhanced cascade reaction as well as a preparation method and application of the core-crosslinked nano-drug. The core-crosslinked nano-drug is prepared from polylysine-ferrocene, polyethylene glycol-poly (lysine-cyclodextrin)-polyglutamic acid, glucose oxidase and cis-platinum in a mass ratio of 1: 2: 1.2: 0.7. The core-crosslinked nano-drug based on the dual-enhanced cascade reaction can effectively avoid premature leakage of the drug and has good stability, and the preparation method is simple. Compared with the prior art, the nuclear cross-linked nano-drug based on the dual-enhanced cascade reaction combines chemotherapy, chemodynamic therapy and hunger therapy, and the anti-tumor treatment effect is greatly improved through a combined treatment system of a combined therapy of the chemotherapy, the chemodynamic therapy and the hunger therapy.

The invention provides maslinic acid PROTACs as well as a preparation method and application thereof, and belongs to the technical field of drug development. According to the invention, maslinic acid is taken as a POI ligand, lenalidomide and fluoro-thalidomide are taken as E3 ligands, and linker selects a PEG chain or an aliphatic chain, so that the anti-cancer activity of the compound is superior to that of maslinic acid, and the compound has a good potential application prospect in the aspect of anti-tumor treatment.